EpithalonWhat the studies show

Q: What kind of evidence exists for epitalon?

Animal and lab studies. Cell and animal studies from one Russian laboratory, and small open-label human cohorts of the pineal extract it copies; no independent replication and no placebo-controlled trial.

A four-amino-acid copy of a pineal gland extract, from a St Petersburg laboratory that reported telomerase activation in human cells in 2003.

5 min read · Animal and lab studies · Updated November 2026

In short

Name: epitalon (sold by Progression Labs as Epithalon)
Evidence: Animal and lab studies
Bottom line: Cell and animal studies from one Russian laboratory, and small open-label human cohorts of the pineal extract it copies; no independent replication and no placebo-controlled trial.

Before you read this

This guide explains what published studies found. That is all it is.

It is not medical advice and it is not instructions for using anything. Where a dose appears, we are reporting what a named study gave the people or animals in it — a fact about the study, not an instruction to you.

The compounds here are not approved by the FDA for use in people and are sold for laboratory research only. A study tells you what happened to the subjects in it; it does not tell you what would happen to you. Talk to a doctor first.

What it is

Epitalon (also spelled epithalon) is a synthetic peptide of four amino acids: alanine, glutamate, aspartate and glycine. It was designed in the late 1990s by Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology as a short copy of epithalamin, an extract of the pineal gland that the same institute had been giving to animals and to elderly patients since the 1980s ¹. Almost everything published about it comes from that group and its collaborators, much of it in Russian journals or in English translations of them. It is not approved as a drug by the FDA or the European Medicines Agency.

The studies below call this molecule epitalon. Progression Labs sells it as Epithalon; the guide uses the store's name and the papers use theirs.

The rest of this guide is free

Unlock the Epithalon guide — and every other one

What the studies found, what they didn't, every source linked. Enter your email once; the link we send opens all of them on this device, plus one plain-language study breakdown a week.

Telomerase in a dish

The result that made epitalon's name was published in 2003. Human fetal fibroblasts, which normally have no telomerase activity, were grown with the peptide, and the cultures showed telomerase activity and longer telomeres than untreated cultures ². Telomeres are the protective ends of chromosomes that shorten each time a cell divides; most adult cells cannot rebuild them, which is one reason cultured cells stop dividing after a fixed number of passages. A follow-up from the same group in 2004 reported that fibroblasts grown with epitalon kept dividing past the passage number at which the control cultures stopped ³.

Both are reports from one laboratory, in a journal of short communications, with small numbers of cultures and without the independent replication that a result of this size would normally attract. They are also results in cells. Telomerase activation in a person would raise its own questions, since the enzyme is what most cancers switch on to divide without limit.

Monkeys and mice

In 2001 the group gave epitalon to aged rhesus monkeys whose evening melatonin, the pineal hormone that signals night, had fallen to a fraction of young animals' levels; after treatment the evening rise returned, and the daily rhythm of cortisol looked more like that of young monkeys ⁴. That is the clearest animal result, and it fits the peptide's origin as a pineal extract.

Lifespan was tested in mice. In a 2003 study, female mice given epitalon from early adulthood for the rest of their lives did not live longer on average than untreated mice, but the last survivors lived somewhat longer, and fewer treated mice developed spontaneous tumours ⁵. Mouse lifespan studies are sensitive to strain, housing and chance, and this one has not been repeated by another laboratory.

Elderly patients in Russia

The human evidence is the part most often misdescribed. The studies with long follow-up used epithalamin, the pineal extract, and thymalin, a thymus extract, in several hundred elderly patients followed for several years, and reported lower mortality in the treated groups than in untreated controls ¹. They were open-label, not placebo-controlled, and all from the group that developed the preparations. There is no randomised, placebo-controlled trial of the synthetic tetrapeptide in people, and no published measurement of telomere length in anyone who has received it.

What to make of it

Taken together: a mechanism that would be remarkable if it holds up, shown in cells by one group; animal results on hormone rhythms and tumours that fit the story; and human cohorts that tested a different preparation without a placebo. The gap between that and a claim about human lifespan is the whole of the evidence pyramid. An independent replication of the 2003 telomerase result, in cells, would be the single most informative study anyone could run, and as far as the published record shows it has not been done.

What these studies are, and aren't

Animal and lab studies. Cell and animal studies from one Russian laboratory, and small open-label human cohorts of the pineal extract it copies; no independent replication and no placebo-controlled trial.